RxDoctor Payments Data

Christopher Smith, MD

Infectious Disease · Baltimore, MDNPI 1053817981

Payments from drug & device makers

$21,766in general payments, 2019–2025

Across 108 payments — averaging $201.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$21K
  • Viiv Healthcare Company$652
  • Merck$149
  • AbbVie$83
  • Baxter Healthcare$28
  • Stryker$26

What the payments were for

  • Consulting fees$2,67012%
  • Speaking & faculty fees$12,51057%
  • Travel & lodging$2,0639%
  • Food & beverage$4,47621%
  • Education$180%
  • Other$280%

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Gilead91$20,829
Viiv Healthcare Company6$652
Merck8$149
AbbVie1$83
Baxter Healthcare1$28
Stryker1$26

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$21,766 in reported general payments places this provider in the 75th percentile of 289 infectious disease providers in Maryland.

See all infectious disease providers in Maryland

Medicare billing

Part B allowed, 2024
$7,372
Medicare patients
44
Services billed
76

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala500$1,939,701
DovatoDolutegravir Sodium/Lamivudine115$327,946
CabenuvaCabotegravir/Rilpivirine37$184,214
SymtuzaDarunavir/Cob/Emtri/Tenof Alaf37$166,878
JulucaDolutegravir/Rilpivirine46$151,802
TivicayDolutegravir Sodium32$72,369
JardianceEmpagliflozin86$65,259
OdefseyEmtricitab/Rilpiviri/Tenof Ala14$48,038
GenvoyaElviteg/Cob/Emtri/Tenof Alafen12$45,025
TriumeqAbacavir/Dolutegravir/Lamivudi11$36,910
OzempicSemaglutide38$35,067
PifeltroDoravirine11$21,304
Trelegy ElliptaFluticasone/Umeclidin/Vilanter32$19,770
TrulicityDulaglutide14$17,692
MyrbetriqMirabegron31$16,607

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Genvoya$20,829$1,984,727512 claims
Viiv Healthcare CompanyDovato, Cabenuva, Juluca, Tivicay, Triumeq$652$773,241241 claims
MerckPifeltro$149$21,30411 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 289 infectious disease providers in Maryland.

Other infectious disease in Baltimore

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →